drugset / Trial / NCT03932864

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

NCT03932864

Phase 1 Completed 107 enrolled Ensoma
RandomizedSequentialQuadruple-blindTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in healthy volunteers as a single agent and in combination with plerixafor.

Timeline

Start
2019-04-22
Primary completion
2020-02-25
Completion
2020-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject MGTA-145 Protein / enzyme biologic Intravenous
Subject Plerixafor Small molecule 240 ug/kg Subcutaneous

Indications

No indication recorded.